A new dementia drug candidate developed by domestic researchers has signed a technology export contract with overseas pharmaceutical companies for the largest amount ever.
The Ministry of Science and ICT and the Korea Institute of Science and Technology said KIST startup Curebus has signed a large technology transfer agreement with Italian pharmaceutical company Angelini Pharma.
This technology transfer is CV-01 (CV holiday), a new drug candidate for dementia that entered the first phase of clinical trials in September this year, and if it succeeds in commercializing a total of 370 million dollars, including advance payments and step-by-step technology fees, 503.7 billion won in our money.
This is the largest-ever achievement in technology transfer by a research institute company founded based on its contribution to science and technology.
'CV-01' is a method of regulating brain inflammation by activating the Nrf2 (NRF2) protein, which is known to maintain cell homeostasis, and is composed of low-molecular drugs with small particle sizes and absorbed well into our body.
If it is developed as an edible drug and is successfully commercialized, it will be possible for elderly patients to easily and periodically take it at home.
※ 'Your report becomes news'
[Kakao Talk] YTN Search and Add Channel
[Phone] 02-398-8585
[Mail] social@ytn.co.kr
[Copyright holder (c) YTN Unauthorized reproduction, redistribution and use of AI data prohibited]